trial

Cognitive Effects of Adjuvant Vortioxetine in Early Schizophrenia

NCTId NCT04895488
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Unknown
Enrollment 37 (estimated)
Sponsored by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Primary completion 2024-12-20
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Unknown
Enrollment
37 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
None
Start
2022-01-20
Primary completion
2024-12-20
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
VortioxetineUsual Antipsychotic Treatment

Sponsors

Fundación Pública Andaluza para la gestión de la Investigación en SevillaLead Sponsor

Investigators

1
Benedicto Crespo Facorro, ProfessorPrincipal Investigator

Sites

1 total
Seville, Spain

Linked catalysts

1
Cognitive Effects of Adjuvant Vortioxetine in Early Schizophrenia — primary completion2024-12-20

Facts & assertions

4 sourced
Enrollment
37
Phase
PHASE2,PHASE3
Primary Completion Date
2024-12-20
Status
UNKNOWN
relationships
The graph out of here
drug
Vortioxetine
drug
Usual Antipsychotic Treatment
drug
lead_sponsor
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
company
indication
Cognitive Impairment With Primary Psychotic Disorder
indication
Negative Symptoms With Primary Psychotic Disorder
indication
investigator
Benedicto Crespo Facorro, Professor
person